Genmab

	26/10 16:41 af E L	i hope that means the expansion phase is starting? maybe we can get some data at ASH ?
	26/10 16:35 af E L	The Phase 1 Talquetamab trial changed into a Phase 1/Phase 2 and increases enrollment from 185 to 245 (link)
	26/10 15:29 af Solsen	It looks good EL - thanks.
	26/10 14:08 af nohope	Ok. Great :-)
	26/10 12:17 af E L	Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer (link)
	26/10 12:16 af E L	and...
	26/10 12:16 af E L	is that Mariposa? we will not have to wait for that. they have breakthrough therapy designation from the FDA
	26/10 11:26 af nohope	Estimated Study Completion Date : November 20, 2025
	26/10 11:24 af nohope	Estimated Primary Completion Date : April 30, 2024
	26/10 11:11 af E L	I think Amivantamab is vastly underrated.... JNJ is throwing a lot of effort into it and i think it will be filed sooner as expected -> double royalties at no cost to genmab
	26/10 11:10 af GeorgeBest	Agree
	26/10 11:09 af E L	GEN1046 could be the jackpot if it works as good as Jan thinks... but it will still take some time; i don't think the data in november will be able to show us the full potential yet
	26/10 11:00 af GeorgeBest	Specielt epco og GEN1046 er ekstremt vigtige da Genmabs ejerandel er 50%
	26/10 10:58 af GeorgeBest	På lang sigt skal aktien up up and away. Pga epco, GEN1046, Amivantamab, Kesimpta. Genmab går fra at være en one trick pony, til et multiblockbuster biotech selskab
	26/10 10:50 af Vitus	Er der ellers nogle holdninger til aktien :-)
	26/10 10:21 af Plimsoller	Still doesn't work after closing the browser, but I will reboot after work. Thanks for your help :-)
	26/10 10:18 af E L	turned nicely on the 2194 Thursday low, let's see if it can turn into a small double bottom
	26/10 10:17 af E L	just close your browser & open again, or refresh page and should be fine
	26/10 10:13 af troldmanden	tror det er noget med når man ikke har haft PC slukket og den blot er i dvale. Uret viser også stadig sommertid i chatten hos mig
	26/10 10:10 af Helge Larsen/PI-redaktør	Her virker det fint på alle enheder. :-)
	26/10 09:58 af Plimsoller	Mon PC tid er fin, men tiden på chatten er ikke. Jeg genstarter når jeg får tid. Tak for info :-)
	26/10 09:57 af Plimsoller	Jeg sidder på Frederiksberg, så det tror jeg ikke :-)
	26/10 09:52 af Plimsoller	Tidsangivelserne på beskederne er en time foran. Måske er det kun på min skærm?
	26/10 09:40 af Helge Larsen/PI-redaktør	Hvilket Plimsoller...Uret funker fint i chatten?

	26/10 09:19 af transalp	Go morgen.. :)
	26/10 08:06 af Plimsoller	Jeg tror at du skal have lavet det om til vintertid Helge :-)
	26/10 08:05 af Plimsoller	God morgen :-)
	26/10 07:11 af Helge Larsen/PI-redaktør	God morgen. :-)
	25/10 11:22 af E L	ah, ok, misundertanding solved ;-) we are on the same line then
	25/10 10:45 af Bulder	Am I misunderstanding you? I think belamaf will not play any role because of eye problem.
	25/10 10:20 af E L	ok. i judged that differently, thought it could be a major problem. We'll just have to beat them on efficacy then ;)
	25/10 10:08 af Bulder	Yes, I think it will not play any role in the earlier lines. A bit like Selinexor.
	25/10 08:58 af E L	@Bulder , that wouldn't make any difference for the eye problems I imagine, that would probaby be the same for new jpatients?
	25/10 08:36 af Helge Larsen/PI-redaktør	God morgen. :-)
	24/10 17:05 af Helge Larsen/PI-redaktør	ANMELDELSE - BOBLER, BULLSHIT OG BØRSFEST : (link)
	24/10 16:00 af Bulder	.. refractory to these agents.
	24/10 15:59 af Bulder	... "all patients were exposed to bortezomib, lenalidomide, pomalidomide and daratumumab, and 80% of patients were exposed to carfilzomib." Thus for heavily pretreated pt s refrsc
	24/10 15:12 af E L	table 3: (link) Keratopathy 96% any grade, 75% (!) grade 3 or 4
	24/10 15:08 af E L	Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study (link)
	24/10 09:45 af E L	Identifying CD38+ cells in patients with multiple myeloma: first-in-human imaging using copper-64–labeled daratumumab (link)
	24/10 09:07 af Helge Larsen/PI-redaktør	Stoxx: Europæiske health care aktier fortsat under pres pgr af ventet Biden sejr(link)
	23/10 21:15 af GeorgeBest	(link)
	23/10 21:14 af GeorgeBest	A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
	23/10 17:36 af Helge Larsen/PI-redaktør	Genmab @Genmab · 2 t Close collaboration with top research institutions is part of our DNA at Genmab. We are excited to announce our new partnership with @PrincetonChem , which will pair experts in academia and our researchers to explore new areas of antibody research: (link)
	23/10 17:31 af Helge Larsen/PI-redaktør	I lige måde. :-)
	23/10 14:00 af E L	yes, it will be for the next generation i think, Hexabody-CD38 will be tested in DLBCL
	23/10 13:56 af Bulder	Men bortset fra det, så blev dara jo klinisk testet i NHL for år tilbage med skuffelse til følge. Tvivler på, det bliver taget op igen. (link)
	23/10 13:40 af DevOp	anything below 7-8% after a week like this is discarded :-)
	23/10 13:34 af nohope	He xaneken 3,8% ?
	23/10 13:23 af E L	;-)